Drugs.com - Pharma Industry News

ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

TUESDAY, June 3, 2025 -- For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor...

Jun 3, 2025 - 18:55
 0
ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
TUESDAY, June 3, 2025 -- For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor...
Read More

Tags:

Previous Article

ASCO: Disease-Free Survival Prolonged With Exercise Program in Colon Cancer

Next Article

Chronic Cannabis Smoking, THC Ingestion Linked to Endothelial Dysfunction

Related Posts

Higher Social Media Use Tied to Subsequent Depressive Symptoms in Youth

Higher Social Media Use Tied to Subsequent Depressive S...

May 23, 2025  0

Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk

Metabolic Dysfunction-Linked Steatotic Liver Disease Ti...

May 20, 2025  0

Intravenous Tenecteplase Beneficial Before Endovascular Thrombectomy

Intravenous Tenecteplase Beneficial Before Endovascular...

May 23, 2025  0